Sanpras - instructions for use, reviews, analogs and formulations (tablets 40 mg, injections in ampoules for injection of lyophilizate) drugs for the treatment of gastric ulcer and gastritis, duodenal ulcer in adults, children and during pregnancy. Composition

In this article, you can read the instructions for using the drug SunPraz. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of specialists in the use of Sanpras in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Sanpras with available structural analogues.Use to treat gastric ulcers and gastritis, duodenal ulcers, reflux esophagitis in adults, children, as well as during pregnancy and breast-feeding. Composition of the preparation.

SunPraz - inhibitor of H-K-ATPase. It blocks the final stage of the secretion of hydrochloric acid (hydrochloric acid), reduces the level of basal and stimulated (regardless of the type of stimulus) secretion of hydrochloric acid (hydrochloric acid) in the stomach. With duodenal ulcer associated with Helicobacter pylori (Helicobacter), a decrease in gastric secretion increases the sensitivity of the microorganism to antibiotics.

Does not affect the motility of the gastrointestinal tract. Secretory activity is normalized 3-4 days after the end of the drug intake.

Composition

Pantoprazole sodium sesquihydrate + excipients.

Pharmacokinetics

After taking the drug inside, SanPraz is quickly absorbed from the digestive tract. Bioavailability of 65-77%. Intensively metabolized in the liver, mainly with the participation of the enzyme system CYP2C19. The main metabolite in blood plasma and urine is desmethylpentoprazole, conjugated with sulfate. Most of the drug is excreted by the kidneys in the form of inactive metabolites.In small quantities is excreted through the intestine. In patients with renal insufficiency, the pharmacokinetics do not change significantly.

Indications

• peptic ulcer of the stomach and duodenum (in the phase of exacerbation), erosive gastritis (including associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs));
• gastroesophageal reflux disease (GERD): erosive reflux-esophagitis (treatment), symptomatic treatment of GERD (ie NERB - non-erosive reflux disease);
• Zollinger-Ellison syndrome;
• eradication of Helicobacter pylori in combination with antibacterial agents;
• treatment and prevention of stress ulcers, as well as their complications (bleeding, perforation, penetration).

Forms of release

Tablets, coated with enteric coating 40 mg.

Lyophilizate for the preparation of a solution for intravenous administration (injections in ampoules for injections).

Instructions for use and dosing regimen

Pills

With peptic ulcer of the stomach and duodenum, erosive gastritis, the drug is prescribed for 40-80 mg per day. The course of treatment for exacerbation of peptic ulcer of the duodenum is 2 weeks, and gastric ulcer is 4-8 weeks.

For prevention of exacerbations of peptic ulcer of the stomach and duodenum, 20 mg per day are prescribed.

To eradicate Helicobacter pylori take 40 mg twice a day in combination with antimicrobial agents. The course of therapy is 7-14 days.

With erosive and ulcerative lesions of the stomach and duodenum associated with the administration of NSAIDs, 40-80 mg per day is prescribed. The course of treatment is 4-8 weeks. For the prevention of erosive lesions against the background of prolonged use of NSAIDs - 20 mg per day.

With reflux-esophagitis appoint 20-40 mg per day. The course of therapy is 4-8 weeks. For the prevention of exacerbations take 20 mg per day.

In patients with severe impairment of liver function, the dose should be reduced to 40 mg once every 2 days, while biochemical blood counts should be monitored. When the activity of hepatic enzymes is increased, the drug should be discontinued.

Tablets are taken internally as a whole (without crushing or dissolving), with a sufficient amount of liquid. The drug is recommended to take 1 h before breakfast, with the frequency of reception 2 times a day, the second dose - 1 hour before dinner.

Ampoules

This dosage form of Sunprase is indicated only for intravenous administration. The drug is recommended only in cases where oral administration of Pantoprazole is not indicated.As soon as oral therapy becomes available, IV administration should be discontinued.

The recommended dose for intravenous administration is the administration of the contents of one vial (40 mg pantoprazole) once a day. Data on intravenous administration can be used within 7-10 days, prolongation of the course of treatment depends on the clinical need.

With prolonged treatment of Zollinger-Ellison syndrome and other pathological hypersecretory conditions, the recommended daily dose at the beginning of treatment is 80 mg of Sanpras. After this, the dose may be increased or decreased. If the drug is used in a daily dose of more than 80 mg, the dose should be divided and administered 2 times a day. Perhaps a temporary increase in the daily dose to 160 mg of Sanpras.

With the eradication of Helicobacter pylori in combination with antibacterial agents, the recommended daily dose is 80 mg of Sanprasse for 7-10 days, the dose should be divided and administered twice a day.

In severe violations of liver function, the daily dose should be reduced to 20 mg of pantoprazole. In addition, during treatment with the drug, such patients need regular monitoring of the activity of liver enzymes. In the case of increased activity of hepatic enzymes, treatment should be discontinued.

Older patients, as well as patients with impaired renal function (including patients on hemodialysis) do not need to increase the daily dose of pantoprazole 40 mg.

Rules for preparation and administration of the drug

Before the injection, the contents of the vial must be reconstituted with 10 ml of 0.9% sodium chloride solution.

This solution is injected or infused after mixing with 100 ml of 0.9% sodium chloride solution, 5% glucose solution or 10% glucose solution. The pH of the ready-to-use solution should be within 9-10.

The duration of administration should be 2-15 minutes. The prepared solution should be used within 3 hours after preparation.

Side effect

• headache;
• depression;
• hallucinations (especially in predisposed patients);
• disorientation and confusion;
• dizziness;
• impaired vision;
• pain in the upper abdomen;
• diarrhea, constipation;
• flatulence;
• nausea, vomiting;
• dry mouth;
• arthralgia;
• myalgia;
• leukopenia, thrombocytopenia;
• anaphylactic reactions, including anaphylactic shock;
• hives;
• angioedema;
• itching;
• skin rash;
• severe skin reactions (Stevens-Johnson syndrome, erythema multiforme, photosensitivity, Lyell's syndrome);
• phlebitis, thrombophlebitis (injection form);
• peripheral edema;
• interstitial nephritis;
• fever.

Contraindications

• dyspepsia of neurotic genesis;
• malignant diseases of the digestive tract;
• lactation period;
• children's age till 18 years;
• hypersensitivity to the drug.

Application in pregnancy and lactation

Experience with the drug during pregnancy and lactation is limited. The drug can be used during pregnancy only if the benefit to the mother exceeds the possible risk to the fetus.

There is no data on the isolation of pantoprazole with breast milk. You should stop breastfeeding while taking the drug.

In experimental studies of reproductive function, slight embryotoxicity was noted in doses exceeding 5 mg / kg.

Use in children

Sanpraz is contraindicated in children and adolescents under the age of 18 years.

special instructions

In the presence of any of the anxiety symptoms (for example, significant unintentional weight loss, recurrent vomiting, dysphagia,anemia or melena) and in case of suspicion or presence of a stomach ulcer, the possibility of malignant neoplasm should be excluded. treatment with pantoprazole can reduce symptoms and delay the correct diagnosis. If the symptoms persist despite adequate treatment, further examination should be carried out.

Before and after treatment, endoscopic control is necessary to exclude the possibility of having malignant diseases of the stomach or esophagus, because the treatment can mask the symptoms and delay the correct diagnosis.

Impact on the ability to drive vehicles and manage mechanisms

The use of the drug does not affect the patient's ability to perform work requiring increased attention and speed of psychomotor reactions.

Drug Interactions

Simultaneous application of Sanpraz can reduce the absorption of drugs, the bioavailability of which depends on the pH of the stomach (including ketoconazole, iron salts, ritonavir).

With the joint application of Sanpraz with atazanavir, plasma concentrations of atazanavir decrease and its therapeutic effect decreases.

In carrying out specific tests of Sanpras with such drugs as digoxin, nifedipine, metoprolol, amoxicillin, clarithromycin, oral contraceptives (levonorgestrel / ethinyl estradiol), diclofenac, phenazone, naproxen, piroxicam, glibenclamide, levothyroxine sodium, diazepam, carbamazepine, phenytoin, cyclosporin, tacrolimus, cisapride, midazolam, metronidazole, theophylline, caffeine, ethanol (alcohol), no clinically significant interaction was found.

According to post-marketing data, when taking a drug with warfarin, prothrombin time increases, which can lead to bleeding, up to a lethal outcome. It is recommended to determine prothrombin time.

Analogs of the drug Sunpras

Structural analogs for the active substance:

• Zipantola;
• Controllers;
• Crosatide;
• Nolpaz;
• Pantaz;
• Pantoprazole sodium sesquihydrate;
• Panum;
• Pepazol;
• Pienzhenum Sanovel;
• Puloreph;
• Ulter.

Analogues for the pharmacological group (proton pump inhibitors):

• Acrylase;
• Vimovo;
• Gastrozole;
• Dexylant;
• A zerocide;
• Zolser;
• Zulbeks;
• Controllers;
• Lanzabel;
• Lanzap;
• Lansoprazole;
• Lansofed;
• Lancid;
• Losek;
• Nexium;
• Nolpaz;
• Нофлюкс;
• Omez;
• Omez D;
• Omez Insta;
• Omeprazole;
• Omizak;
• Ortanol;
• Pantaz;
• Parries;
• Pepazol;
• Pepticum;
• Pylobact;
• Rabelock;
• Rabeprazole sodium;
• Romesque;
• Ulcozol;
• Ulter;
• Ultop;
• Hirabesol;
• Helithrix;
• Helicid;
• Helol;
• Cisagast;
• Esomeprazole;
• Emanera;
• Epicurus.

Similar medicines:

Other medicines: